Salud financiera de hoja de balance de Neuren Pharmaceuticals
Salud financiera controles de criterios 6/6
Neuren Pharmaceuticals tiene un patrimonio de accionistas total de A$205.2M y una deuda total de A$0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son A$248.0M y A$42.8M respectivamente. El BAIT de Neuren Pharmaceuticals es de A$199.2M, por lo que su ratio de cobertura de intereses es de -35. Tiene efectivo e inversiones a corto plazo que ascienden a A$228.5M.
Información clave
0%
Ratio deuda-patrimonio
AU$0
Deuda
| Ratio de cobertura de intereses | -35x |
| Efectivo | AU$228.54m |
| Patrimonio | AU$205.21m |
| Total pasivo | AU$42.76m |
| Activos totales | AU$247.97m |
Actualizaciones recientes sobre salud financiera
Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business
Jan 07
We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth
Sep 06Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth
May 31We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn
Feb 03Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation
Aug 06We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth
May 05Recent updates
An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued
Apr 01Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically
Mar 05Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors
Mar 02Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors
Dec 18Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues
Sep 02Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)
Aug 31This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year
Mar 03Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business
Jan 07We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth
Sep 06Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth
May 31We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn
Feb 03Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation
Aug 06We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth
May 05Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)
Feb 19Have Insiders Been Selling Neuren Pharmaceuticals Limited (ASX:NEU) Shares This Year?
Jan 04
Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo (A$247.2M) de NEU superan a sus pasivos a corto plazo (A$42.8M).
Pasivo a largo plazo: NEU no tiene pasivos a largo plazo.
Historial y análisis de deuda-patrimonio
Nivel de deuda: NEU está libre de deudas.
Reducción de la deuda: NEU no ha tenido ninguna deuda en los últimos 5 años.
Cobertura de la deuda: NEU no tiene deuda, por lo tanto no necesita estar cubierta por flujo de caja operativo.
Cobertura de intereses: NEU no tiene deuda, por lo que la cobertura de pagos de intereses no es motivo de preocupación.